eganp

6 ms·

1.
by eganp 3y ago
IIRC, this is still true if you exclude the spike protein and use a higher similarity threshold. Why would one do that? Well, two reasons. First, the spike more variable as it is subject to greater evolutionary pressure as the major compone
2.
by eganp 4y ago
This doesn't test the "epigenetic information theory of aging." First, there is no survival analysis. How is the mouse younger if it doesn't live longer? Similarly, the OSK "rejuvenated" mice display lower le
3.
by eganp 4y ago
I'm surprised the insurance will pay for this. The judgment, and actions by Oberlin's administration, strongly suggest they were acting in bad faith. The college's behavior exceed negligence, the typical threshold in these so
4.
by eganp 4y ago
$1M in seed funding, but at what valuation? I hope the terms are near market.
5.
Evolution of antibodies from general protein language models and sequence alone(biorxiv.org)
2 points by eganp 4y ago|0 comments
6.
by eganp 5y ago
Never thought of this distinction before! Thanks for making this distinction. This seems to hold in other contexts. People tend to tolerate price discrimination at an aggregate level (e.g. senior/student discounts) but loathe individua
7.
by eganp 5y ago
Paywall Bypass: https://archive.md/gi57Y
8.
The Dark Proteome – many of our proteins remain hidden(cen.acs.org)
7 points by eganp 5y ago|1 comments
9.
by eganp 5y ago
There a quite a few things missing from this paper that would make it a good a good drug discovery paper. First, they didn't discover a drug - they found a hit. 30 days from target to hit using conventional high-throughput biochemical
10.
by eganp 5y ago
NIH likely funds 2/3rds of US biomedical research and ~1/3rd of global biomedical research by dollar value [0]. That link lists other big sources (ERC, MRC, US DoD, HHMI). My sense is that this landscape will change rather quickly
11.
by eganp 5y ago
Somewhat surprised asymmetric organocatalysis was awarded over asymmetric photocatalysis or photoredox chemistry. Photocatalysis is newer, has more demonstrated use cases, and holds more promise.
12.
by eganp 5y ago
The list price will nearly always be a multiple of your cost with insurance. The issue here is that insurers have provisions in their network contracts that prevent providers from publically advertising lower prices than what's charged
13.
by eganp 5y ago
Some insurers (looking at you United Health Care) have wholly owned PBMs. Thus, the PBM is an asset in its insurance trust. Any profit the PBM makes will appear as in increase in asset valuation for their insurance trust, or balance sheet i
14.
by eganp 5y ago
Unfortunately this is pretty accurate. Pharmacy Benefit Managers (PBMs) are contracted by insurers to set the formulary, in effect the list of drugs the insurer will pay for. They negotiate to lower drug costs, usually via manufacturer re
15.
by eganp 5y ago
I worked with a group trying to get a drug repurposing study running in June of last year. U01 submissions were often Sept-Aug with no cash until April 2021. To a degree, these NOTs and RFAs are deeply unserious and woefully underfunded. Th
16.
by eganp 5y ago
I'm glad we did. Vaccines were a home-run solution. In a crisis, what does academic R+D get you on the margin? Better testing for sure, but that wouldn't solve the crisis like vaccines would. I will say the drug repurposing landsc
17.
by eganp 5y ago
This study is looking at the appendix, not any brain tissue. Without considering symptoms, it's possible that altered PrP expression and/or folding in the appendix does not cause vCJD or result from exposure to PrP(Sc). Also, thes
18.
by eganp 5y ago
Dangerous? The hypothesized connection is not remotely clear. In vitro transformation of human PrP into PrP(Sc) by bovine PrP(Sc) is a necessary for the causal model. The fact that a strong species barrier exists, in vitro and in vivo, poin
19.
by eganp 5y ago
Intracranial inoculation of infected tissue is the old-school way to assay for prion activity. Sometimes it takes a few years to get an answer though, especially in cross-species assays [0]. [0] https://link.springer.com/cha
20.
by eganp 5y ago
This probably isn't possible as the folding of PrP is not encoded in the mRNA of PRNP. The fold of PrP is a post-translational phenomenon, much like its glycosylation. This is true for many mammalian proteins, especially cell-surface p
21.
by eganp 5y ago
The species barrier in prion transmission appear very strong [0]. Transmitting a prion from a hamster into a mouse often takes multiple passages of direct in brain inoculation. In these closely related species, perhaps it's less stron
22.
by eganp 5y ago
The risk of cow->human BSE transmission is infinitesimal. Species barriers in prions are surprisingly strong and, for practical purposes, nearly impermeable [0]. In fact, the Prion Protein (PrP) in humans causes multiple distinct disease
23.
by eganp 6y ago
Clearly open access has costs, but how does Nature Photonics get to $40k/paper?? Is that how much revenue they expect to derive from the lifetime of the paper?
24.
by eganp 6y ago
It's a tough lift to demonstrate that all such modified-mRNA vaccines are safe and likely effective. This trial is a good validation of off-target safety, and that's a huge achievement. However, you still have on-target safety con
25.
by eganp 6y ago
Hey refoundable - great interview! Love Jack's characterization of Alzheimers as chemical roulette. Just wanted to let you know there's a typo in your first figure. "Thalyidamide" should be "thalidomide" [0]. I
26.
Cocaine Receptor Identified as BASP1(biorxiv.org)
2 points by eganp 6y ago|0 comments
27.
by eganp 6y ago
This is a nice essay but I think it misses 3 key points: 1. FTC returns are predictable. The returns to taking an unbeaten path is anything but. Further, how will your peers and the world view you as CEO of New Idea Inc vs. L4 at Google? 2.
28.
by eganp 6y ago
How much of this compensation is equity appreciation? Is it realistic to expect this 10 years from now? Not like interest rates can get lower or search could get less competitive.
29.
by eganp 6y ago
Ok let's suppose that consulting salaires hit $1M by age 40. What fraction of new hires make senior consultant? Partner? If your firm is operating on leverage of 20:1, sure you can make $2-20M annually. But, realistically, what are you
30.
by eganp 6y ago
I wish I knew this coming out of school. I think this is also another reason why people prefer prestigious schools. Those who own and operate these cash machines tend to send their children to elite schools. I can't even begin to count

More ›